Bionano Genomics, Inc. (BNGO) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 4 Buy, 3 Hold.
The consensus price target is $46.50 (low: $1.00, high: $175.00), representing an upside of 3743% from the current price $1.21.
Analysts estimate Earnings Per Share (EPS) of $-80.10 and revenue of $0.03B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-60.05 vs est $-80.10 (beat +25%). 2025: actual $-4.85 vs est $-6.40 (beat +24.2%). Analyst accuracy: 67%.
BNGO Stock — 12-Month Price Forecast
$46.50
▲ +3,742.98% Upside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Bionano Genomics, Inc., the average price target is $46.50, with a high forecast of $175.00, and a low forecast of $1.00.
The average price target represents a +3,742.98% change from the last price of $1.21.
Highest Price Target
$175.00
Average Price Target
$46.50
Lowest Price Target
$1.00
BNGO Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to Bionano Genomics, Inc. in the past 3 months
EPS Estimates — BNGO
67%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$60.05
vs Est –$80.10
▲ 33.4% off
2025
Actual –$4.85
vs Est –$6.40
▲ 31.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — BNGO
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.031B
vs Est $0.029B
▲ 6.4% off
2025
Actual $0.029B
vs Est $0.028B
▲ 0.2% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
